抗肿瘤药物的治疗效果应该以提高病人的生存质量为准,还是以通过替代指标进行评价,成为一个争议性问题。近期,华尔街日报(10/28)在网络上对该争论进行了调查并提供了实时报道。该调查指出《密尔沃基前哨报》和《今日医学新闻》提供的分析数据表明,通过评价过去十年中54例肿瘤治疗案例发现将近3/4的肿瘤患者生存期没有延长,生存质量没有提高。该结果使诸如肿瘤尺寸的减小等替代指标在抗肿瘤治疗中的应用越来越受 Whether the therapeutic effect of antineoplastic drugs should be based on improving patients’ quality of life or evaluating them through alternative measures has become a controversial issue. Recently, the Wall Street Journal (10/28) surveyed the controversy over the internet and provided real-time coverage. The survey states that the data provided by the Milwaukee Sentinel and Today’s Medical News show that by evaluating 54 cancer treatment cases over the past decade, nearly three-fourths of patients with cancer found no longer survival and did not have an improved quality of life. This result makes the use of alternative indicators such as reduced size of the tumor more and more antitumor therapy